Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection
- PMID: 12589955
- DOI: 10.1111/j.1574-695X.2003.tb00646.x
Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection
Abstract
Here we describe a lethal mouse model infected with dengue virus type 2 with several similarities to human DEN-2 infection. Clinically animals demonstrated anemia, thrombocytopenia, pre-terminal paralysis and shock. The most impressive changes were seen with tumor necrosis factor (TNF)-alpha, which abruptly and steeply increased 24 h before the exitus (mean at day 6). Serum levels of IL-1beta, IL-6, IL-10, IL-1 receptor antagonist and soluble TNF receptor I continuously increased during the time of infection. A 100% mortality rate was noted in that group of animals. Treating animals with anti-TNF-alpha serum reduced mortality rate down to 40% (P<0.05). Our model supports the view that activation of innate immune response is at least partially responsible for mortality in DEN-2 infection, and in line with this concept, anti-TNF treatment significantly reduces mortality rates.
Similar articles
-
Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice.J Virol. 2015 Jun;89(11):5847-61. doi: 10.1128/JVI.00216-15. Epub 2015 Mar 18. J Virol. 2015. PMID: 25787279 Free PMC article.
-
Acute Systemic Infection with Dengue Virus Leads to Vascular Leakage and Death through Tumor Necrosis Factor-α and Tie2/Angiopoietin Signaling in Mice Lacking Type I and II Interferon Receptors.PLoS One. 2016 Feb 4;11(2):e0148564. doi: 10.1371/journal.pone.0148564. eCollection 2016. PLoS One. 2016. PMID: 26844767 Free PMC article.
-
Murine model for dengue virus-induced lethal disease with increased vascular permeability.J Virol. 2006 Oct;80(20):10208-17. doi: 10.1128/JVI.00062-06. J Virol. 2006. PMID: 17005698 Free PMC article.
-
The development of therapeutic antibodies against dengue virus.Antiviral Res. 2016 Apr;128:7-19. doi: 10.1016/j.antiviral.2016.01.002. Epub 2016 Jan 19. Antiviral Res. 2016. PMID: 26794397 Review.
-
Autoimmune pathogenesis in dengue virus infection.Viral Immunol. 2006 Summer;19(2):127-32. doi: 10.1089/vim.2006.19.127. Viral Immunol. 2006. PMID: 16817755 Review.
Cited by
-
Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage.Elife. 2013 Apr 30;2:e00481. doi: 10.7554/eLife.00481. Elife. 2013. PMID: 23638300 Free PMC article.
-
Activation of Nrf2 by the dengue virus causes an increase in CLEC5A, which enhances TNF-α production by mononuclear phagocytes.Sci Rep. 2016 Aug 26;6:32000. doi: 10.1038/srep32000. Sci Rep. 2016. PMID: 27561946 Free PMC article.
-
Association of dengue virus-specific polyfunctional T-cell responses with clinical disease severity in acute dengue infection.Immun Inflamm Dis. 2019 Dec;7(4):276-285. doi: 10.1002/iid3.271. Epub 2019 Sep 30. Immun Inflamm Dis. 2019. PMID: 31568656 Free PMC article. Clinical Trial.
-
Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice.J Clin Invest. 2011 Nov;121(11):4446-61. doi: 10.1172/JCI57682. Epub 2011 Oct 17. J Clin Invest. 2011. PMID: 22005300 Free PMC article.
-
Dengue virus infection: current concepts in immune mechanisms and lessons from murine models.Immunology. 2014 Feb;141(2):143-56. doi: 10.1111/imm.12188. Immunology. 2014. PMID: 24182427 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases